Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Spotlight Correspondence
  • Published:

D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients

Leukemia volume 19, pages 2332–2333 (2005)Cite this article

TO THE EDITOR

In Leukemia (January 2005),1 Dr Piazza reported a BCR-ABL mutation D276G by sequencing the BCR-ABL tyrosine kinase (TK) domain of Ph+ leukemic cells from 14 imatinib-resistant patients. The mutation was associated with aggressive chronic myeloid leukemia (CML), while in vitro functional analysis using mutants demonstrated moderated resistance.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Piazza RG, Magistroni V, Gasser M, Andreoni M, Galietta A, Scapozza L et al. Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to imatinib. Leukemia 2005; 19: 132–134.

    Article  CAS  Google Scholar 

  2. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876–880.

    Article  CAS  Google Scholar 

  3. Barthe C, Cony-Makhoul P, Melo JV, Reiffers J, Mahon FX . Roots of clinical resistance to STI-571 cancer therapy. Science 2001; 293: 2163.

    Article  CAS  Google Scholar 

  4. Larghero J, Leguay T, Mourah S, Madelaine-Chambrin I, Taksin AL, Raffoux E et al. Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo. Biochem Pharmacol 2003; 66: 1907–1913.

    Article  CAS  Google Scholar 

  5. Azam M, Latek RR, Daley GQ . Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003; 112: 831–843.

    Article  CAS  Google Scholar 

  6. Warmuth M, Simon N, Mitina O, Mathes R, Fabbro D, Manley PW et al. Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. Blood 2003; 101: 664–672.

    Article  CAS  Google Scholar 

  7. Deininger M, Buchdunger E, Druker BJ . The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105: 2640–2653.

    Article  CAS  Google Scholar 

  8. von Bubnoff N, Veach DR, van der Kuip H, Aulitzky WE, Sanger J, Seipel P et al. A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor. Blood 2005; 105: 1652–1659.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratoire Hématopoïèse normale et pathologique, FRE CNRS 2617, Université Victor Ségalen, Bordeaux Cedex, France

    T Leguay, V Desplat, G Marit & F-X Mahon

  2. Service des Maladies du Sang, Hôpital du Haut-Lévèque, Pessac, France

    T Leguay, G Marit & F-X Mahon

Authors
  1. T Leguay
    View author publications

    Search author on:PubMed Google Scholar

  2. V Desplat
    View author publications

    Search author on:PubMed Google Scholar

  3. G Marit
    View author publications

    Search author on:PubMed Google Scholar

  4. F-X Mahon
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to T Leguay.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Leguay, T., Desplat, V., Marit, G. et al. D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients. Leukemia 19, 2332–2333 (2005). https://doi.org/10.1038/sj.leu.2403993

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/sj.leu.2403993

Search

Advanced search

Quick links